In one breath
Eli Lilly’s revenue has more than doubled in two years, and its profit margin is now the highest in a decade. The stock trades at roughly 50 times last year’s earnings, yet that multiple sits in the bottom quarter of its own history, because earnings have grown faster than the price. The open question is whether the two drugs carrying almost all of that growth can keep compounding at this pace, or whether the market is already pricing in a version of the future that the pipeline has not yet earned.
Four years that remade a century-old company
For most of its 150-year life, Eli Lilly was a solid, mid-speed pharmaceutical company: dependable insulin franchises, a handful of branded medicines, and the kind of steady single-digit growth that kept pension funds comfortable. Then, in May 2022, the FDA approved Mounjaro (tirzepatide) for type 2 diabetes. That approval was the hinge. Tirzepatide works on two hormonal pathways simultaneously, producing weight loss that earlier diabetes drugs could not approach, and when the obesity indication followed, the company found itself at the center of the most commercially significant drug category in a generation.
The revenue line tells the story in numbers. FY2023 revenue was $34.1 billion, already a step up. FY2025 revenue reached $65.2 billion. That is not incremental pharmaceutical growth. That is a company being rebuilt around two products while the rest of the portfolio keeps running.
What the most recent quarter actually filed
The 10-Q for the quarter ended June 30, 2026 is the freshest evidence. Revenue for that single quarter was $23.0 billion, up nearly half from the same quarter a year earlier. To feel the scale: that one quarter nearly matches the company’s entire annual revenue for 2020, which was $24.5 billion. Mounjaro alone brought in just under ten billion dollars for the quarter, nearly doubling year-over-year. Zepbound added roughly five billion more. Together, those two drugs account for roughly two-thirds of total quarterly revenue, which is the concentration risk hiding inside the growth story.
The gross margin filed for Q2 2026 was 85.8%, meaning that for every dollar of sales, Lilly kept 86 cents after the direct cost of making the drug. That is a figure more commonly associated with software than with a company running manufacturing plants at scale. R&D spending for the quarter was $3.8 billion, roughly what the entire company earned in profit per quarter just three years ago, signaling that management is betting heavily on what comes next rather than harvesting what already exists.
Following these results, Lilly raised its full-year 2026 revenue guidance to a range of $85 billion to $87 billion, up from a prior range. That is management saying, in public and on the record, that the demand signal is running ahead of their own earlier estimates.
The math and the mood
Here is the tension that makes this company worth examining. “The math” is what the filed fundamentals justify on their own terms. “The mood” is what the market is currently paying, independent of those fundamentals. Usually the gap between them is the story.
The math, as our data shows, is genuinely unusual. The FY2025 net margin of 31.7% is the highest in the decade of filings we track, roughly double what it was just two years prior. Earnings per share for 2025 represent earnings growing nearly four times faster than the stock price over the same period. The operating margin filed in the FY2025 10-K was 40.4%, meaning four of every ten revenue dollars became operating profit, a figure that most pharmaceutical companies spend careers trying to approach.
The mood, at a price near $1,192, implies a trailing P/E of roughly 50 times last year’s earnings, per our data. That sounds expensive until the context arrives: our data shows that Lilly’s own decade-median P/E is 65.6, and the current multiple sits at the 27th percentile of its own history. The market is paying less, relative to earnings, than it has for most of the past ten years, even as those earnings have compounded dramatically. The price-to-sales ratio sits near its decade median, per our data, suggesting the revenue growth has been absorbed into the price more evenly than the earnings growth has.
The simplest way to hold both readings: the stock has risen meaningfully over the past twelve months, per our data, but earnings per share nearly doubled over the same period. The earnings ran faster than the price. That is the math outrunning the mood, which is the less common direction for the gap to run.
The pipeline bet
The total debt on the FY2025 balance sheet, measured against free cash flow of $8.97 billion that year, means the company is carrying roughly five years of free cash flow in debt. That is not alarming for a company growing at this rate, but it does mean the pipeline must keep delivering. The debt was largely accumulated through an aggressive acquisition strategy: BiSpace reported Lilly spent over $25 billion across ten transactions in 2026 to expand into infectious diseases and deepen its oncology work.
The next chapter is already being written in clinical data. Retatrutide, a drug that works on three hormonal pathways rather than two, showed average weight loss of up to 28.3% over 80 weeks in Phase 3 trials, with results from the TRIUMPH-2 and TRIUMPH-3 trials announced July 23, 2026. A regulatory submission is expected in Q1 2027. Meanwhile, the FDA granted Breakthrough Therapy designation to olomorasib for advanced pancreatic cancer on August 4, 2026, a cancer with historically poor treatment options, marking a second such designation for the drug.
The oral GLP-1 pill Foundayo, approved in April 2026, is the wildcard. Its early quarterly sales fell well short of expectations, as FiercePharma reported, suggesting that patients and physicians are not yet switching from injectables at the pace the market had assumed. Whether that is a slow start or a structural ceiling is a question the filed numbers cannot yet answer.
On the analyst side, BMO Capital raised its valuation estimate to $1,400 on August 6, 2026, while Morningstar, as of July 29, 2026, characterized the shares as overvalued given current market expectations. Both views are coherent given the same set of facts, which is itself informative: the range of reasonable interpretations is wide.
Reading the numbers
- Q2 2026 revenue: $23.0 billion. Filed in the 10-Q for June 30, 2026. This is what the company collected in a single quarter. A household earning $100,000 a year would need 230,000 years to match it. It means the growth is not slowing: the same quarter last year produced $15.5 billion, so the company added the equivalent of a mid-sized pharmaceutical company’s annual revenue in twelve months.
- Gross margin: 85.8%. Also filed in the Q2 2026 10-Q. This is what remains of each dollar of sales after paying to manufacture the drug. A bakery keeping 86 cents of every dollar after flour and labor would be extraordinary. For a drug company running physical manufacturing at scale, it signals enormous pricing power relative to production cost.
- FY2025 net margin: 31.7%. Filed in the FY2025 10-K. Net margin is what survives after every bill, tax, and interest payment. In FY2023, this figure was 15.4%, meaning the company roughly doubled its profit efficiency in two years. A restaurant keeping 32 cents of every dollar after rent, staff, and food would be considered exceptional.
- P/E ratio: 50.9 (trailing), decade median 65.6. Our data, computed from filed earnings and market price. A P/E is the price tag per dollar of annual profit, the way a house price-to-rent ratio tells you how many years of rent you are paying upfront. At 50.9, the market is paying about 51 years of current earnings. The decade median of 65.6 means the market has historically paid even more. IF earnings per share hold near the filed-trend trajectory AND the trailing multiple reverts toward its decade median of 65.6, the arithmetic would place the implied price in a materially higher range than today’s ~$1,192; IF earnings growth decelerates toward single-digit rates, the same multiple arithmetic would suggest the current price already reflects a generous premium. Both scenarios are conditional on outcomes the filed numbers cannot yet confirm.
- Total debt: $42.5 billion. Filed in the FY2025 10-K. Free cash flow for the same year was $8.97 billion. Think of it as a household carrying a mortgage of about five times its annual take-home pay. Manageable if income keeps rising, more stressful if it plateaus.
For the standing yardsticks on Eli Lilly &: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Eli Lilly &.
Sources
- Eli Lilly 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Eli Lilly 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Eli Lilly 10-K, fiscal year ended December 31, 2023 (SEC EDGAR)
- Lilly Q2 2026 earnings press release (PR Newswire, August 5, 2026)
- FiercePharma: Foundayo sales and injectable growth, Q2 2026
- BiSpace: Lilly Q2 2026 results and acquisition strategy
- Pharmaceutical Technology: FDA Breakthrough Therapy designation for olomorasib, August 4, 2026
- Investing News: Retatrutide Phase 3 trial results and FDA fast track
- Investing.com: BMO Capital raises Lilly valuation estimate, August 6, 2026
- BullScope published methodology
